Nanoparticles-based drug delivery and gene therapy for breast cancer: Recent advancements and future challenges

• Published in: Seminars in cancer biology Vol. 69; pp. 226 - 237
• Main Authors: Mirza, Zeenat, Karim, Sajjad
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.02.2021
• Subjects: Animals; Antineoplastic Agents - administration & dosage; Breast cancer; Breast Neoplasms - genetics; Breast Neoplasms - pathology; Breast Neoplasms - therapy; Drug delivery; Drug Delivery Systems; Female; Gene therapy; Genetic Therapy; Humans; MicroRNAs - administration & dosage; MicroRNAs - genetics; Nanoparticles; Nanoparticles - administration & dosage; Nanoparticles - chemistry; RNA, Small Interfering - administration & dosage; RNA, Small Interfering - genetics; TNBC; BC; MRI; EPR; Drug delivery; U.S. FDA; Nanoparticles; LHRH; QD; SLNs; miRNA; MDR; SPION; TNBC; CEA; CRISPR; GBNs; siRNA; Breast cancer; Dox; PEG; pDNA; sgRNA; NC; Cas9; HER2; Gene therapy
• ISSN: 1044-579X; 1096-3650
• DOI: 10.1016/j.semcancer.2019.10.020

Breast cancer (BC) is amongst the most lethal cancer among females and conventional treatment methods like surgery, radiotherapy and chemotherapy are not effective enough as expected and suffer concerns of low bioavailability, low cellular uptake, emerging resistance, and adverse toxicities. Gene therapy using free nucleic acids has potential to deal with key candidate genes of BC, but their effect is retarded due to poor cell uptake and instability in circulation. The rapidly evolving field of nanomedicine aiming targeted drug/gene delivery curtailing BC promises to overcome the limitations of conventional therapies. Nanoparticles can be game changer for BC gene therapy as they can be effective carrier of specific drug/gene by improving the circulation time, enhancing bioavailability, reducing the immune system based recognition chances, and delivering the gene regulator accurately. Herein, we discuss the mechanism of nanoparticles targeted drug delivery, recent advancement of therapeutic strategies of nanoparticles based carriers for small interfering RNA, and microRNA, and gene augmentation therapies in BC. We also discuss the future prospect and challenges of nanoparticle-based therapies for BC.